Disney Bans Medical Marijuana

Copyright © 2017 All Rights Reserved
by Erik Muenker D.C. |  Exclusive CBDbusinessBlog.com
 Erik Muenker Editor CBD Business Blog     Twitter  |  Google+  |  Linkedin

Orlando, Florida – May 4th, 2017
Disney Bans Marijuana | Officially No Longer Happiest Place On Earth

Disney Prohibits Medical Marijuana
Disney Prohibits Medical Marijuana

Disney says no to medical marijuana at Disney World.

Yes, the citizens of Florida (over 70% of them) did approve Amendment 2 and legalize medical marijuana on November 8th, 2016. Disney CEO Bob Igor disagrees.

Continue reading “Disney Bans Medical Marijuana”

Americans support for Legal Marijuana Climbs to 60%!

Copyright © 2017 All Rights Reserved
by Erik Muenker D.C. |  Exclusive CBDbusinessBlog.com

HAPPY 420 | Great news to celebrate!

WASHINGTON, D.C. — According to the latest Gallup Poll, the support for legal marijuana stands at an all-time high of 60%!

Gallup Q: “Do you think the use of marijuana should be made legal, or not?

A: 60% said YES, legalize

      Americans approve of legal marijuana!
          * Gallup Poll Oct. 2016

Continue reading “Americans support for Legal Marijuana Climbs to 60%!”

Silver Leaf Investment: An upstart marijuana investment company to watch in 2017

Copyright © 2017 All Rights Reserved
by Erik Muenker D.C. |  Exclusive CBDbusinessBlog.com

Marijuana is Growing Fast

The legal cannabis (marijuana) industry is booming. According to Forbes.com, it was worth an estimated $7.2 billion in 2016. With double digit annual growth, adult recreational sales alone are expected to jump from $2.6 billion in 2016 to $11.2 billion by 2020.

In addition to recreational sale, medical marijuana sales are expected to more than double to $13.3 billion by 2020. That’s a combined annual market of over $24 billionanticipated in just the next 3 years.

Does AG Sessions worry you?

Jobs, state’s rights, and taxes. That’s right. Jobs, state’s rights and tax revenue are the cannabis industry’s secret weapons against marijuana detractors in the Trump administration and elsewhere.

According to a survey conducted by Marijuana Business Daily, the marijuana industry already employs over 100,000 people in the U.S. alone.

Along with billions in sales, comes millions in tax revenue. Motley Fool estimated that in 2016, Colorado’s marijuana tax haul likely exceeded $200 million. That’s a lot of green. And it’s only going to continue to grow each year.

Continue reading “Silver Leaf Investment: An upstart marijuana investment company to watch in 2017”

Spotlight: Marijuana company Canopy Growth now in S&P/TSX Index

Copyright © 2017 All Rights Reserved
by Erik Muenker D.C. |  Exclusive CBDbusinessBlog.com

 

Canopy_Growth_Corporation_logo.svg

SMITH FALLS, Ontario – Another milestone for the cannabis industry was reached today

Canopy Growth [TSX:WEED], Canada’s largest and arguably most successful marijuana company – has been added to the S&P/TSX Composite Index. The index represents nearly 70% of the total market capitalization on the Toronto Stock Exchange and is considered a key benchmark for the Canadian equity market.

With the addition of Canopy Growth to the index, more and more investors will now be buying and holding weed.

Canopy Growth has a market capitalization of $780.6 million and a year-to-date stock price change of +192%. Canopy Growth is definitely a cannabis company to watch in 2017.


Update – March 27th, 2017
Legal Marijuana in Canada by 2018
Legal Marijuana in Canada by 2018

According to the CBC, PM Tradeau will announce legislation on April 10th – to legalize marijuana for recreational use in Canada by July 1, 2018!

Shares of Canopy Growth Corp. jumped 11% in trading on the news.

Continue reading “Spotlight: Marijuana company Canopy Growth now in S&P/TSX Index”

Celebrating Powerful Women in Weed on International Women’s Day

Copyright © 2017 All Rights Reserved
by Erik Muenker D.C. |  Exclusive CBDbusinessBlog.com

The CBD Business Blog

would like to celebrate

International Women’s Day

by celebrating

Powerful Women In Weed

Women in Weed Lg
Powerful Women in Weed

Trump Pick For FDA Could Help Marijuana Industry | But At What Cost?

Copyright © 2017 All Rights Reserved
by Erik Muenker D.C. |  Exclusive CBDbusinessBlog.com
Jim O’Neill Could Bring Disruption and Marijuana to the FDA
Jim O'Neill - FDA-candidate
Jim O’Neill Courtesy Mithri Capital

According to Bloomberg News and TheHill, President Donald Trump is strongly considering Jim O’Neill, an outspoken marijuana supporter and libertarian, to be the next head of the FDA. Jim O’Neill has been a staunch critic of the FDA for years and if appointed to lead the agency, he is likely to usher in dramatic changes that could shake the agency to its core. And maybe, just maybe, that’s not such a bad thing.

Peter Thiel
Peter Thiel – Trump transition team

Jim O’Neill is reportedly a close business associate of key Trump transition team member Peter Thiel – a tech financier worth more than $2 Billion. Theil was named #246 on the Forbes 400 List of Richest People in America in 2016. Theil spokesman Jeremiah Hall was quoted recently in an email reported by Bloomberg Politics, “Jim O’Neill has extensive experience in government and in Silicon Valley. He is a strong candidate for any of several key positions.”

Mr. O’Neill is currently the Managing Director of Mithril Capital Management LLC,

mithril

a global investment firm cofounded by Peter Thiel. Previous to Mithril Capital, Mr. O’Neill spent just under six years working in various roles for the Department of Health and Human Services during the George W. Bush Administration, from 2002 – 2008. O’Neill first served as the Director of the Speech and Editorial Division, then as Associate Deputy Secretary and ultimately as the Principal Associate Deputy Secretary contributing to policy and regulatory matters affecting the FDA.

In addition to working for the Dept. of HHS, O’Neill also served on the Board of Directors (and was a founding member) for the Coalition for Cannabis Policy Reform. CCPR is a nonpartisan organization which opposes prohibition and supports reasonable marijuana regulation. O’Neill is likely to bring big changes to the FDA, easing research and perhaps access to cannabis based pharmaceuticals and nutraceuticals.

Continue reading “Trump Pick For FDA Could Help Marijuana Industry | But At What Cost?”

Cannabidiol and Marijuana News and Views | @CBDbusinessBlog on Twitter

Follow-Us-On-Twitter-2017
Follow Us On Twitter

Interested in the Legal Marijuana Industry?

Follow the CBD Business Blog on Twitter and stay up-to-date on all of the latest marijuana industry news, with a focus on cannabidiol (CBD) – the amazing nutraceutical found in cannabis.


About the Author
Erik Muenker D.C. – Portland, OR
Founder and Editor of CBD Business Blog |  Twitter: @CBDbusinessBlog

CBD-BB Logo and URLDr. Erik Muenker D.C. is the Publisher and Editor of the CBD Business Blog, an online blog and journal – your source for exclusive business, scientific, health and political news impacting the recreational and medical marijuana industries.

Our focus is on cannabidiol (CBD), a non-addictivenon-psychotropic and medically powerful cannabinoid found in marijuana and hemp.                Disclaimer

Marijuana: The Big Weed Money on Vice News

Vice News: The Big Weed Money

VICE News gets an exclusive look inside Canopy Growth Corp., the Canadian marijuana producer that calls itself the world’s largest legal weed company.

After the Vice video about the Canopy Growth Corp was published, it was subsequently restricted to the UK audience alone.

Link to UK restricted video. Once the video is republished without this restriction I will update this post with the new version.

Until then, I have substituted the video with another from Vice News – intended for the U.S. audience:

So far the company has only been allowed to sell to medical patients, but that will all change when prime minister Justin Trudeau makes good on his promise to legalize marijuana for recreational purposes. And that’s especially good news for Canopy, which has been gearing up to dominate the future recreational market for years, even though the government hasn’t yet even unveiled its legalization plan. This year, its subsidiary Tweed announced a partnership with Snoop Dogg, and it became the first weed company to list on a major stock exchange.

But there’s questions around the corporation’s deep ties to the ruling Liberal party, and how much influence it has over government policy and who will get left out of Canada’s future weed regime.

Cannabis CBD Extract Market Booming | 700% Growth Projected

Copyright © 2017 All Rights Reserved
by Erik Muenker D.C. |  Exclusive CBDbusinessBlog.com

Cannabidiol (CBD) is one of two principle cannabinoids found in marijuana and hemp plants. It has well documented neuroprotective, anti-oxidant and anti-inflammatory applications. It is non-psychoactive, has few known side-effects, and is well tolerated by the young, elderly and all those in between.

CBD preparations are marketed as both a nutraceutical (e.g. CBD oil extracts, transdermal gels, vape concentrates, edibles, etc.) and as a prescription-only pharmaceutical (e.g. Epidiolex, see below for more).

A flurry of new scientific research into CBD therapeutics is showing extremely promising results. CBD is lining up to be the “next big thing” in the Health and Wellness Industry. The CBD market for 2015 was estimated at $202 million.

The Hemp Business Journal just released a report forecasting that the consumer CBD market will grow to $2.1 billion in sales by 2020! GreenWave Advisors, an independent research and financial analysis firm, is even more bullish and projects a $3 billion CBD market by 2021!

CBD legalization is here

CBD-only preparations (hemp based CBD extracts) are legal for purchase online in the majority of states in the U.S. 15 states explicitly allow for the sale of CBD-only products, with an additional 28 states where CBD extracts are also available thru regulated medical or recreational dispensaries.

CBD-BB=United-States-election-results-MarijuanaClick here, to learn more about the 2016 election results and what it all means to the future of the cannabis industry and the CBD market.

CBD as a Medicine

CBDs effectiveness in treating severe forms of epilepsy is also well documented. Although still in early clinical trials, CBD preparations are saving the lives of children with severe early-onset, life-threatenting forms of epilepsy such as Dravet Syndrome and Lennox-Gastaut Syndrome.

GW Pharmaceuticals, a UK based company focused on cannabis plant-derived therapeutics, is quickly making a name for itself as a leading manufacturer of a pharmaceutical grade cannabidiol extract – Epidiolex. Epidiolex is currently under-going FDA approved clinical trials and the results are more than promising. Early reports point to a potential 50% – 75% reduction in the occurrence of seizures.

Click this link for a summary of the most recent physician reported data that was presented to the American Epilepsy Society at their annual meeting in December 2015. More information is available at GWpharma.com.

Learn more about CBD with this CBD 101A CBD Business Blog Exclusive
CBD Oil for Schizophrenia
New research suggests that high doses of CBD could have anti-cancer properties and may one day be part of a wholistic anti-cancer regiment. But don’t let the FDA hear you say that. Big pharma still owns the market on FDA approved cancer treatments. As a result, you won’t see many CBD oil/extract manufacturers advertising medical benefits for their (highly effective) products.

Cannabis Oncology and Cancer

CBD and Cervical CancerDid you know that half of all cancer patients are killed by Chemotherapy – NOT CANCER?

A recent marijuana study actually concluded that CBD inhibits and kills cervical cancer cells. Click the image for a link to this exclusive article.

Continue reading “Cannabis CBD Extract Market Booming | 700% Growth Projected”

UK Gov Concedes CBD (cannabidiol) from Cannabis is Medicine

CBD News Pick – Independent.co.uk

Exclusive: The MHRA’s assessment could ‘provide ground-breaking results’ in leading to reform over cannabis’ medicinal use in the UK

The government’s Medicines and Healthcare products Regulatory Agency (MHRA) has found that Cannabidiol (CBD) has a “restoring, correcting or modifying” effect on “physiological functions” when administered to humans, in a potential milestone in the campaign to legalise cannabis and bring about evidence-based laws regarding drugs.

The review of CBD, a cannabinoid accounting for up to 40% of the marijuana plant’s extract that doesn’t contain its psychoactive THC but is purported to retain the health benefits, came about following discussions with CBD vaporiser company MediPen.

uk-gov-admits-cbd-a-medicine

The MHRA’s findings are not directly applicable to the government’s response to last year’s petition to legalise cannabis, but stand in stark contrast, with the petition having been batted away by the Home Office with the assessment that cannabis “can unquestionably cause harm to individuals and society”.

GW Pharmaceuticals has also just concluded a positive phase 3 clinical trial demonstrating the safety and efficacy of CBD.

“Since our inception we’ve worked hard to obtain our goal of breaking down the negative connotations surrounding Cannabis to lead to a reform in the law for medicinal use,” Jordan Owen, Managing Director of MediPen, told The Independent, “now this is finally becoming a reality, which will provide ground-breaking results,”

Click here to continue reading the published article.


CBD-BB-Logo10

For original content on the cannabis industry, plus news articles and insider views | handpicked by the CBD Business Blog Editor | to keep you informed on cannabis and cannabidiol (CBD) industry news:

Subscribe to our Newsletter today!

Cannabis Conference ICBC comes to Vancouver Oct 13-14

CBD News Pick – Vancouver Sun

At Vancouver’s next big weed get-together, you can expect less tie-dye and more suit-and-tie.

Organizers of the International Cannabis Business Conference this week at the Hyatt Regency Hotel in downtown Vancouver expect a crowd of 650 or more to attend over Thursday and Friday.

And with tickets to attend the conference running upwards of $600 each, the event might have more of a corporate feel than the average 4/20 rally.

There has been no shortage of cannabis conferences passing through Vancouver in recent months: the Cannabis Hemp Conference came to the Westin Bayshore in July, and last month brought both Canadian Cannabis Business Week and the Lift Cannabis Expo to downtown Vancouver.

But the International Cannabis Business Conference seeks to differentiate itself from other events with its global scope and ambitions, said conference organizer and founder Alex Rogers this week. The first editions of the conference were held in San Francisco and Portland, and next April, organizers will take it to Berlin. Plans are in motion, Rogers said, for 2018 events in Australia and Croatia.

Rogers has lived and worked in five different countries, including a six-month jail sentence in Germany after a conviction for cannabis trafficking, an experience he said prompted him to “make the decision to get my life together.”

“I am international citizen,” he said. “I’m a global soul. So my goal was always to take this international.”

Rogers said it is no coincidence that Vancouver will be the first city outside the U.S. to host his event, adding: “Historically speaking, Vancouver is one of the cannabis capitals of the world.”

“I think it’s up to Canada and Vancouver to stay the leaders in this game,” he said. “They need smart, progressive policy that keeps Vancouver and Canada a leader in the cannabis world for another 100 years.”

Speakers at this week’s event include Dr. Gabor Mate, a Vancouver-based physician renowned for his writing about the science of addiction, and Kirk Tousaw, a lawyer and cannabis reform advocate. Tommy Chong, another cannabis legend with ties to Vancouver, will also appear.

Friday’s keynote speaker will be Brendan Kennedy, CEO of Privateer Holdings, a private company based in Seattle with employees in five countries (including about 130 Canada), and ambitions to be a leader in both the medicinal and recreational cannabis markets.

Privateer subsidiary Tilray, a federally licensed cannabis production facility on Vancouver Island, made history this year by becoming the first Canadian company to legally export medical marijuana overseas, said Kennedy, adding: “We’ve always viewed this industry as a global industry.”

Click here to continue reading the published article.


CBD-BB-Logo10

For original content on the cannabis industry, plus news articles and insider views | handpicked by the CBD Business Blog Editor | to keep you informed on cannabis and cannabidiol (CBD) industry news:

Subscribe to our Newsletter today!

Pennsylvania’s First Marijuana Farm?

CBD News Pick – Pittsburg Post Gazette

Laurel Green Medical aims to get state approval to supply medical marijuana

Denise Gargasz-Mueller and David Knepshield were checking out a 6.5-acre dirt lot at an Armstrong County industrial park last week, all the while envisioning a future in the cannabis growing industry.

In a matter of months, this bare flat could be the site of one of Pennsylvania’s first legal cannabis growing facilities, the home base of a company that’s already lining up medical marijuana dispensary locations in Sewickley, Cranberry and possibly Mt. Lebanon and the Strip District.

Just a few years ago, these two entrepreneurs would have made an unlikely pairing:

Mr. Knepshield is the former CEO of Ford City-based Klingensmith Healthcare, a home medical equipment supply company, while Ms. Gargasz-Mueller, who comes from a farming family, has spent the last four years lobbying to get medical marijuana legalized in Pennsylvania.

With legalization now on the books and the first dispensaries due to open in 2018, their partnership “brings all the right ingredients together,” she said.

Their fledgling company, Laurel Green Medical, has already done a lot of things right — meeting with local officials to line up community support, bringing legal and scientific specialists onboard, and setting out a detailed business plan for attracting investors.

The company is applying for one of the five state-allowed “seed-to-sell” licenses that would allow the partners to grow, process and dispense. They expect to find out if their application is approved around March of next year.

Their goal is simple, said Ms. Gargasz-Mueller: To provide high-quality medical cannabis in a safe, compassionate and discreet environment.

But they also know that while the medical marijuana industry has seen explosive growth the past five years, lurking in the background is a federal law that still considers their product illegal.

So far, Mr. Knepshield said, no major banks here want to touch the medical marijuana business, even though federal officials have indicated they will leave it to state and local agencies to enforce their own narcotics laws.

“Any bank that is federally regulated will not have anything to do with this. It’s not illegal for them to do it. They just don’t feel comfortable with it yet.”

Diane Czarkowski, who with husband Jay started one of the first cannabis dispensaries and cultivation operations in Colorado in 2009, said that’s not uncommon.

“We went through eight banks, but we did finally find one that realized they could get some new business by addressing this industry,” said Mrs. Czarkowski, who has since left the dispensary business and now offers consulting services for cannabis startup businesses through the couple’s company, Canna Advisors.

Laurel Green hopes to work with smaller, state-chartered banks and credit unions to the extent they can; to the extent they can’t, this will be a cash business handling millions of dollars. So, yes, security will be a priority.

“This place will be Fort Knox,” promised Mr. Knepshield.

Like other states that have recently legalized medical marijuana such as New York, New Jersey and Maryland, Pennsylvania is going to require applicants to show they have the financial wherewithal to make a go of it.

Just to apply for the license to grow, process and dispense medical marijuana, Laurel Green Medical has to produce a non-refundable $10,000 payment. The company has to put down another $200,000, which is refundable if the application is denied, for the license. And the partners must demonstrate they have the capital backing to pull the whole thing off, including documentation they have another $500,000 in the bank and another $2 million in assets.

Click here to continue reading the published article.


CBD-BB-Logo10

For original content on the cannabis industry, plus news articles and insider views | handpicked by the CBD Business Blog Editor | to keep you informed on cannabis and cannabidiol (CBD) industry news:

Subscribe to our Newsletter today!